市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | NuCana plc | 混合的 | 混合的 |
AIStockmoo 评分
| 价值 35% | -1.7 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -1.7 |
| 时机 35% | -1.3 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -0.5 |
| 技术平均移动指标 参考 | -2.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -36.3% |
| 支柱一致性 | ×1.25 |
| 不计入评分 | |
| 价格波动 参考 | 1.2 |
| 最终评分 | -1.59 |
|
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 机构持股比例 | 0.15% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Glass Jacobson Investment Advisors Llc | 30 Sep 2026 | 15,000 |
投资组合